Literature DB >> 23599930

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.

Edru Erbayat Altay1, Elizabeth Fisher, Stephen E Jones, Claire Hara-Cleaver, Jar-Chi Lee, Richard A Rudick.   

Abstract

OBJECTIVE: To assess the reliability of new magnetic resonance imaging (MRI) lesion counts by clinicians in a multiple sclerosis specialty clinic.
DESIGN: An observational study.
SETTING: A multiple sclerosis specialty clinic. PATIENTS: Eighty-five patients with multiple sclerosis participating in a National Institutes of Health–supported longitudinal study were included. INTERVENTION: Each patient had a brain MRI scan at entry and 6 months later using a standardized protocol. MAIN OUTCOME MEASURES: The number of new T2 lesions, newly enlarging T2 lesions, and gadolinium-enhancing lesions were measured on the 6-month MRI using a computer-based image analysis program for the original study. For this study, images were reanalyzed by an expert neuroradiologist and 3 clinician raters. The neuroradiologist evaluated the original image pairs; the clinicians evaluated image pairs that were modified to simulate clinical practice. New lesion counts were compared across raters, as was classification of patients as MRI active or inactive.
RESULTS: Agreement on lesion counts was highest for gadolinium-enhancing lesions, intermediate for new T2 lesions, and poor for enlarging T2 lesions. In 18% to 25% of the cases, MRI activity was classified differently by the clinician raters compared with the neuroradiologist or computer program. Variability among the clinical raters for estimates of new T2 lesions was affected most strongly by the image modifications that simulated low image quality and different head position.
CONCLUSIONS: Between-rater variability in new T2 lesion counts may be reduced by improved standardization of image acquisitions, but this approach may not be practical in most clinical environments. Ultimately, more reliable, robust, and accessible image analysis methods are needed for accurate multiple sclerosis disease-modifying drug monitoring and decision making in the routine clinic setting.

Entities:  

Mesh:

Year:  2013        PMID: 23599930      PMCID: PMC3792494          DOI: 10.1001/2013.jamaneurol.211

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  28 in total

1.  Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach.

Authors:  M P Sormani; L Bonzano; L Roccatagliata; G L Mancardi; A Uccelli; P Bruzzi
Journal:  Neurology       Date:  2010-06-23       Impact factor: 9.910

Review 2.  Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis.

Authors:  M Filippi; M A Horsfield; P S Tofts; F Barkhof; A J Thompson; D H Miller
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

3.  Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study.

Authors:  M Filippi; D W Paty; L Kappos; F Barkhof; D A Compston; A J Thompson; G J Zhao; C M Wiles; W I McDonald; D H Miller
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

4.  Eight-year follow-up study of brain atrophy in patients with MS.

Authors:  E Fisher; R A Rudick; J H Simon; G Cutter; M Baier; J-C Lee; D Miller; B Weinstock-Guttman; M K Mass; D S Dougherty; N A Simonian
Journal:  Neurology       Date:  2002-11-12       Impact factor: 9.910

5.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Authors:  Gavin Giovannoni; Giancarlo Comi; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Peter Chang; Anthony Hamlett; Bruno Musch; Steven J Greenberg
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

6.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

7.  Defining interferon beta response status in multiple sclerosis patients.

Authors:  Richard A Rudick; Jar-Chi Lee; Jack Simon; Richard M Ransohoff; Elizabeth Fisher
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

9.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.

Authors:  Peter A Brex; Olga Ciccarelli; Jonathon I O'Riordan; Michael Sailer; Alan J Thompson; David H Miller
Journal:  N Engl J Med       Date:  2002-01-17       Impact factor: 91.245

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  27 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

Review 3.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

4.  Improved Detection of New MS Lesions during Follow-Up Using an Automated MR Coregistration-Fusion Method.

Authors:  A Galletto Pregliasco; A Collin; A Guéguen; M A Metten; J Aboab; R Deschamps; O Gout; L Duron; J C Sadik; J Savatovsky; A Lecler
Journal:  AJNR Am J Neuroradiol       Date:  2018-06-07       Impact factor: 3.825

Review 5.  Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Authors:  Claudio Gasperini; Luca Prosperini; Mar Tintoré; Maria Pia Sormani; Massimo Filippi; Jordi Rio; Jacqueline Palace; Maria A Rocca; Olga Ciccarelli; Frederik Barkhof; Jaume Sastre-Garriga; Hugo Vrenken; Jette L Frederiksen; Tarek A Yousry; Christian Enzinger; Alex Rovira; Ludwig Kappos; Carlo Pozzilli; Xavier Montalban; Nicola De Stefano
Journal:  Neurology       Date:  2018-12-26       Impact factor: 9.910

Review 6.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

7.  Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields.

Authors:  M Cabezas; J F Corral; A Oliver; Y Díez; M Tintoré; C Auger; X Montalban; X Lladó; D Pareto; À Rovira
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-09       Impact factor: 3.825

8.  Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Authors:  Luca Prosperini; Francesco Saccà; Cinzia Cordioli; Antonio Cortese; Fabio Buttari; Simona Pontecorvo; Assunta Bianco; Serena Ruggieri; Shalom Haggiag; Vincenzo Brescia Morra; Ruggero Capra; Diego Centonze; Giancarlo Di Battista; Elisabetta Ferraro; Ada Francia; Simonetta Galgani; Claudio Gasperini; Enrico Millefiorini; Massimiliano Mirabella; Carlo Pozzilli
Journal:  J Neurol       Date:  2016-11-22       Impact factor: 4.849

Review 9.  Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.

Authors:  Suradech Suthiphosuwan; David Kim; Aditya Bharatha; Jiwon Oh
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

10.  Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.

Authors:  Josa M Frischer; Stephen D Weigand; Yong Guo; Nilufer Kale; Joseph E Parisi; Istvan Pirko; Jay Mandrekar; Stephan Bramow; Imke Metz; Wolfgang Brück; Hans Lassmann; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2015-08-24       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.